Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dermapharm Holding SE M&A Activity 2020

Feb 19, 2020

97_rns_2020-02-19_f4c323dd-626c-4b30-93f5-26b8e5664e75.html

M&A Activity

Open in viewer

Opens in your device viewer

News Details

Ad-hoc | 19 February 2020 15:57

Dermapharm Holding SE: Acquisition of Allergopharma

Dermapharm Holding SE / Key word(s): Takeover

Dermapharm Holding SE: Acquisition of Allergopharma

19-Feb-2020 / 15:57 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


**Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)

No. 596/2014 on market abuse, as amended (Market Abuse Regulation – MAR)**

Dermapharm Holding SE: Acquisition of Allergopharma

Grünwald, February 19, 2020 – Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) signed a contract via Dermapharm Beteiligungs GmbH to acquire Allergopharma GmbH & Co. KG, based in Reinbek near Hamburg, Germany, a subsidiary of Merck KGaA, Darmstadt, Germany. With the closing of the transaction, Dermapharm Beteiligungs GmbH will acquire 100.00 percent of the shares in the company that specializes in desensitization of allergies. The parties have agreed not to disclose the purchase price.

The purchase agreement is still subject to the approval of the relevant supervisory authority. The Management Board expects the transaction to be completed by the end of the second quarter of 2020.

>End of the Ad hoc announcement<

Contacts

Investor Relations &

Corporate Communications

Britta Hamberger

Phone: +49 (0)89 – 64186-233

Fax: +49 (0)89 – 64186-165

email: [email protected]
cometis AG

Claudius Krause

Phone: +49 (0)611 – 205855-28

Fax: +49 (0)611 – 205855-66

email: [email protected]

19-Feb-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: [email protected]
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 979211
End of Announcement DGAP News Service

show this